ESBL, MBL AND AMPC DETECTION IN MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA (MDRPA) AND PANDRUG RESISTANT PSEUDOMONAS AERUGINOSA (PDRPA) ISOLATED FROM TERTIARY CARE HOSPITALS

Pseudomonas aeruginosa is a leading cause of nosocomial infection. The rise of antibiotic emergence of resistance may vary with different antibiotic treatments. A variety of s-lactamases which include ESBLs, AmpC s-lactamases and metallo-s-lactamases, have emerged as the most worrisome mechanism of resistance among the gram negative bacteria, which pose a therapeutic challenge to the health care settings. Materials and Methods: A total of 190 clinical isolates of Pseudomonas aeruginosa were studied. Detection of AmpC betalactamase was performed by three-dimensional method, whereas detection of ESBL was done by the combined disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) guidelines and MBL were detected by the combined disc diffusion test. Result: A Total 25 strains of Multidrug resistance Pseudomonas aeruginosa (MDR PSA) and 07 of PAN drug resistant Pseudomonas aeruginosa (PDRPA) were studied in this study. In MDRPSA, 56% isolates were confirmed to be positive for AmpC beta-lactamase. Among them, 57% strains were extended spectrum beta-lactamase and both AmpC beta-lactamase and Extended Spectrum Beta-Lactamase co-producer were 24 % and None of enzyme producer were 18% respectively. While in PDRPA case, 86% isolates were confirmed to be positive for AmpC beta-lactamase. Among them, 86% strains were Extended Spectrum BetaLactamase and both AmpC beta-lactamase and Extended Spectrum Beta-Lactamase coproducer were 86 % and None of enzyme producer were 18% and MBL were 100%.